AnaptysBio is a lean Jemperli royalty vehicle with substantial post-2027 cash-flow upside, contingent on GSK’s execution, Sagard paydown, and clinical and legal catalysts.
Overview
AnaptysBio transformed on April 20, 2026, when it spun its clinical-stage R&D business into First Tracks Biotherapeutics and became a virtual royalty-management company with fewer than 10 employees. It earns collaboration revenue, milestones, and tiered royalties—principally from GSK’s Jemperli and potentially from Vanda’s Quimilza—without a direct sales force or manufacturing base. Jemperli generated $331 million of global sales in Q2 2026, up 26% year over year, and $644 million in the first half, up 34%; GSK guides to more than $2.7 billion in peak monotherapy sales. Sagard currently receives royalties on sales below $1.0 billion, but the remaining approximately $299 million payoff is expected in H2 2027, releasing 100% of Jemperli royalties to AnaptysBio. Management targets annual post-spin expenses below $10 million and steady-state EBIT margins above 95%. Q2 collaboration revenue was $27.5 million, 36% above consensus, while GAAP net income of $177.3 million was driven primarily by a non-cash $181.5 million tax benefit. **The key value inflection is the expected 2027 end of Sagard’s royalty diversion.** Near-term catalysts include the October 20, 2026 GSK litigation hearing, Quimilza’s December 12 PDUFA, and Jemperli’s February 2027 rectal-cancer PDUFA. The report’s five-year probability-weighted target is $158.34 versus $50.29 on October 1, 2026.